CMPSCOMPASS Pathways

Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates PR Newswire NEW YORK, July 21, 2026 Major Depressive Disorder Market Poised for Strong Growth as New Drug Innovations...

H.C. Wainwright and Berenberg became the latest firms to downgrade the stock following Eli Lilly's acquisition agreement.

Both ATAI and CMPS stocks were among the top trending on Stocktwits in pre-market trade.

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a post-hoc analysis of support methods used in an open-label Phase 2 study of investigational COMP360 synthetic...

U.S. stock futures edged higher in the overnight session on Wednesday as markets assessed risks from the U.S.-Iran war and the Federal Reserve’s inflation concerns.

The company’s rolling FDA application is underway, with final submission expected in Q4 and launch targeted for H1 2027.

Multiple analysts reiterated optimism on CMPS stock after the company announced 26-week data from its second late-stage trial of COMP360 in treatment-resistant depression.

Compass Pathways posted 26-week data from its trial evaluating COMP360, showing rapid and durable benefits, while maintaining a favorable safety profile.

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the 26-week results (Part B) from its second ongoing Phase 3 COMP006 trial of COMP360, a synthetic, proprietary formulation of psilocybin, for...